drugset / Trial / NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2024-10-20
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 200 mg | Oral |
| Subject | APG-2575 | Small molecule | 400 mg | Oral |
| Subject | APG-2575 | Small molecule | 600 mg | Oral |
| Subject | APG-2575 | Small molecule | 800 mg | Oral |
| Subject | Ibrutinib | Small molecule | 420 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 500 mg/m2 | Intravenous |